BrainStorm Names Former FDA Official Peter Pitts Executive Chairman; Chairman and CMO Depart
BCLI has more than doubled off its 52-week low of $0.459 on light trading volume (0.3× avg).
Summary
BrainStorm Cell Therapeutics appointed former FDA official Peter Pitts as Executive Chairman, while Chairman Jacob Frenkel and CMO Ibrahim Dagher resigned. Pitts received options on 900,000 shares; Frenkel got 100,000 RSUs. The moves aim to advance the NurOwn Phase 3b trial under an FDA Special Protocol Assessment.
Key Events · Executive and Board Changes · BCLI
-
Peter Pitts Named Executive Chairman
Effective July 24, 2026, former FDA Associate Commissioner Peter Pitts becomes Executive Chairman and Chief Strategic Regulatory Officer, taking charge of daily operations and the upcoming Phase 3b NurOwn trial under an FDA Special Protocol Assessment.
-
900,000 Option Grant to Pitts
Pitts received a nonqualified stock option to purchase 900,000 shares at $1.00 per share, vesting over four years. With no base salary or cash bonus, his compensation is entirely equity-based.
-
Chairman Jacob Frenkel Resigns
Jacob Frenkel resigned as Chairman and director on July 24, 2026, and will serve as a consultant. He received 100,000 restricted stock units vesting over nine months, along with acceleration of his outstanding equity.
-
Chief Medical Officer Ibrahim Dagher Departs
CMO Ibrahim Dagher resigned effective July 26, 2026, and will consult for one year. His outstanding equity continues to vest during this period, with full acceleration at the end of the term.
Analysis · BCLI · Life Sciences
A leadership overhaul at BrainStorm Cell Therapeutics—a micro-cap biotech facing a going-concern warning and critically low cash—puts a seasoned regulatory veteran at the helm. Just two months after joining the board, former FDA Associate Commissioner Peter Pitts steps into the roles of Executive Chairman and Chief Strategic Regulatory Officer, directly overseeing the upcoming Phase 3b NurOwn trial under an FDA Special Protocol Assessment. To align his interests with shareholders, Pitts receives a 900,000-share option grant at $1.00. Meanwhile, Chairman Jacob Frenkel resigns and transitions to a consulting role with 100,000 RSUs, and Chief Medical Officer Ibrahim Dagher also departs, moving to a consulting agreement that extends his equity vesting. These moves signal a strategic pivot to late-stage execution, but the equity grants add dilution pressure to a company already reliant on highly dilutive financing.
At the time of this filing, BCLI was trading at $0.92 on OTC in the Life Sciences sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $0.46 to $1.69. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.